Cargando…
Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study
The Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen (REPAIR) trial was a prospective study exploring the efficacy and safety of intravitreal ranibizumab 0.5 mg using an individualized treatment regimen over 12 month...
Autores principales: | Amoaku, Winfried M., Gale, Richard P., Lotery, Andrew J., Menon, Geeta, Sivaprasad, Sobha, Petrillo, Jennifer, Quinn, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454435/ https://www.ncbi.nlm.nih.gov/pubmed/26039355 http://dx.doi.org/10.1371/journal.pone.0128403 |
Ejemplares similares
-
Single intravitreal ranibizumab for myopic choroidal neovascularization
por: Nor-Masniwati, Saidin, et al.
Publicado: (2011) -
Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis, Dimitrios, et al.
Publicado: (2017) -
Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK
por: Claxton, Lindsay, et al.
Publicado: (2014) -
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin, Philip, et al.
Publicado: (2016) -
Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye
por: Stepanov, Alexandr, et al.
Publicado: (2020)